Financials in USD. Standardized financial statements.
A compact view of how Medexus Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $108.33M | $113.05M | $108.10M | $76.70M | $79.66M | $78.11M | $33.86M | $7.75M | $6.21M | $3.78M |
| Revenue Growth? | -4.2% | +4.6% | +40.9% | -3.7% | +2.0% | +130.6% | +336.9% | +24.9% | +64.4% | 0.0% |
| Cost of Revenue? | $51.75M | $53.54M | $48.06M | $38.77M | $37.66M | $22.99M | $10.38M | $3.85M | $2.08M | $998,427 |
| Gross Profit? | $56.58M | $59.51M | $60.04M | $37.93M | $42.01M | $29.44M | $22.52M | $3.90M | $3.43M | $1.89M |
| Gross Margin? | +52.2% | +52.6% | +55.5% | +49.4% | +52.7% | +37.7% | +66.5% | +50.4% | +55.2% | +50.1% |
| Operating Expenses? | $48.36M | $48.72M | $50.08M | $50.01M | $42.90M | $42.30M | $28.18M | $6.10M | $4.22M | $3.79M |
| Operating Income? | $8.22M | $10.79M | $8.49M | -$12.40M | -$1.38M | -$8.15M | -$707,323 | -$2.84M | -$789,545 | -$4.21M |
| EBITDA? | $16.81M | $19.28M | $14.25M | $14.55M | $7.06M | $3.43M | $1.67M | -$2.06M | -$3.35M | -$4.26M |
| Income Before Tax | $1.44M | $106,000 | -$5.04M | -$3.82M | -$31.50M | -$7.80M | -$6.11M | -$3.48M | -$1.83M | -$2.31M |
| Income Tax Expense | -$807,000 | $320,000 | -$6.26M | -$941,000 | -$3.24M | -$844,000 | $222,000 | $0 | $0 | $0 |
| Net Income? | $2.25M | -$214,000 | $1.22M | -$2.88M | -$28.26M | -$6.19M | -$4.88M | -$2.70M | -$1.37M | -$1.77M |
| EPS? | $0.08 | $-0.01 | $0.06 | $-0.15 | $-1.86 | $-0.46 | $-0.48 | $-0.47 | $-0.28 | $-0.37 |
| Diluted EPS? | $0.08 | $-0.01 | $0.06 | $-0.15 | $-1.86 | $-0.46 | $-0.48 | $-0.47 | $-0.28 | $-0.37 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality